
As the FDA's response deadline for Orphazyme's drug candidate arimoclomol draws ever closer, Sunstone Life Science Ventures has opted to sell some of its shares in the biotech company.
As of Friday last week, the investment company owned less than five percent of shares in Orphazyme, meaning it dropped below the large shareholder boundary, according to a stock exchange notification released on Tuesday.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app